circadian associated repressor of transcriptionGenealiases: C1orf51 · CHRONO · GM129
Q-omics provides the consensus-scored CIART profile across patient tissues and cancer cell-line models. CIART expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, CIART is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CIART RNA expression shows 13,243 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight LUSC, KIRC, and SARC as cancer lineages where CIART shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CIART — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CIART survival associations across molecular data types. CIART RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CIART RNA expression–survival associations across cancer types. High CIART expression shows unfavorable associations in LIHC, ACC and STAD, but favorable associations in LUSC, KIRP and LGG. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for CIART RNA expression.
This table summarizes CIART tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CIART. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CIART shows higher tumor expression in KIRC, LIHC, LUAD, LUSC, THCA and BRCA. The KIRC box plot shows higher CIART RNA expression in tumor versus normal tissue (log2 FC = +1.391, t-test p < 0.001).
This table shows molecular features associated with CIART in patient tissues and cancer cell lines. In patient samples, CIART shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, CIART RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and CNS.
